Researcher
Peter Vandenberghe
- Disciplines:Genetics, Systems biology, Medical imaging and therapy, Molecular and cell biology, Other paramedical sciences
Affiliations
- Laboratory for Genetics of Malignant Disorders (Division)
Responsible
From1 Jan 2008 → Today - Department of Human Genetics (Department)
Member
From1 Apr 2009 → Today
Projects
1 - 10 of 19
- Establishing an evidence ecosystem for blood donation deferral criteria in men who have sex with menFrom9 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Map, Join and Drive European Activities for Advanced Therapy Medicinal Product Development and Implementation for Patient and Society BenefitFrom1 Jan 2024 → TodayFunding: Horizon Europe - Health
- PhD project to identify the immune signature after CAR T-cells treatment.From5 Nov 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- DIPITO: valorisation of deep immune profiling and novel immunotherapeutics for oncology.From1 Oct 2021 → TodayFunding: IOF - mandates
- In-depth investigation of patient immune signature after CD19 CAR T-cell therapyFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Integrated PK/PM Model-based Medication Dosing Assist App(lication) in KlinischWerkStation (KWS). Validation Studies of Tacrolimus in (Solid) Organ TransplantationFrom1 Jan 2021 → 31 Dec 2023Funding: IOF - technology validation in lab
- Mechanisms and Diagnosis of Mast Cell and Basophil Activation in Rare Hypersensitivity DisordersFrom1 Nov 2020 → TodayFunding: BOF - doctoral mandates
- Tracking Multiple Myeloma by low-pass sequencing of circulating cell free DNAFrom1 Mar 2019 → 1 Mar 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Circulating cell-free DNA as an alternative gateway to the genetic features of multiple myeloma and as a surrogate marker for disease burden in multiple myeloma.From1 Mar 2019 → 29 Feb 2024Funding: Nonprofit institution or equivalents
- Circulating cell-free DNA: a novel gateway to the genome of Hodgkin/Reed-Sternberg cells in Hodgkin Lymphoma?From1 Jan 2017 → 31 Dec 2020Funding: Foundations, funds and other with scientific goal
Publications
31 - 40 of 229
- Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data(2020)
Authors: Peter Vandenberghe
- Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1(+) Leukemia (vol 19, pg 740, 2011)(2020)
Authors: Thomas Schmidt, Behzad Kharabi Masouleh, Sonja Loges, Sandra Cauwenberghs, Peter Fraisl, Christa Maes, Bart Jonckx, Kim De Keersmaecker, Maria Kleppe, Marc Tjwa, et al.
Pages: 135 - 136 - Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology(2020)
Authors: Isaure Vanmeerbeek, Jenny Sprooten, Sabine Tejpar, Peter Vandenberghe, Abhishek Garg
- Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study(2019)
Authors: Charlotte Maggen, Daan Dierickx, Annouschka Laenen, Kristel Van Calsteren, Peter Vandenberghe, Frédéric Amant
Pages: E551 - E561 - Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes(2019)
Authors: Peter Vandenberghe
Pages: 689 - 697 - Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1(2019)
Authors: Peter Vandenberghe
Pages: 1910 - 1922 - Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis(2019)
Authors: Gregor Verhoef, Michel Delforge, Peter Vandenberghe, Timothy Devos
Pages: 1421 - 1426 - Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder(2019)
Authors: Karolien Goffin, Vibeke Vergote, Thomas Tousseyn, Gregor Verhoef, Annouschka Laenen, Peter Vandenberghe, Daan Dierickx
Pages: 1041 - 1047 - FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia(2019)
Authors: Lucienne Michaux, Peter Vandenberghe
- Potentiation of imatinib by cilostazol in sensitive and resistant gastrointestinal stromal tumor cell lines involves YAP inhibition.(2019)
Authors: Peter Vandenberghe
Pages: 1798 - 1811